Blair William & CO Sarepta Therapeutics, Inc. Transaction History

Blair William & CO

$33.4 Billion
Q3 2024

A detailed history of Blair William & CO transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Blair William & CO holds 49,162 shares of SRPT stock, worth $5.45 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

49,162

Previous 174,282 71.79%

Holding current value

$5.45 Million

Previous $27.5 Million 77.7%

% of portfolio

0.02%

Previous 0.09%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$124.33 - $156.75 $15.6 Million - $19.6 Million	-125,120 Reduced 71.79%	49,162 $6.14 Million
Q2 2024 Aug 12, 2024	BUY	$113.33 - $163.85 $14.9 Million - $21.5 Million	131,112 Added 303.71%	174,282 $27.5 Million
Q1 2024 May 09, 2024	SELL	$93.7 - $141.53 $112,158 - $169,411	-1,197 Reduced 2.7%	43,170 $5.59 Million
Q4 2023 Feb 12, 2024	SELL	$67.31 - $124.76 $807,585 - $1.5 Million	-11,998 Reduced 21.29%	44,367 $4.28 Million
Q3 2023 Nov 09, 2023	BUY	$102.5 - $123.59 $960,425 - $1.16 Million	9,370 Added 19.94%	56,365 $6.83 Million
Q2 2023 Aug 11, 2023	BUY	$106.4 - $157.19 $2.76 Million - $4.08 Million	25,983 Added 123.66%	46,995 $5.38 Million
Q1 2023 May 12, 2023	SELL	$117.53 - $155.99 $83,563 - $110,908	-711 Reduced 3.27%	21,012 $2.9 Million
Q4 2022 Feb 10, 2023	BUY	$100.86 - $132.13 $63,541 - $83,241	630 Added 2.99%	21,723 $2.81 Million
Q3 2022 Nov 09, 2022	SELL	$75.71 - $119.24 $77,224 - $121,624	-1,020 Reduced 4.61%	21,093 $2.33 Million
Q2 2022 Aug 10, 2022	SELL	$62.69 - $88.44 $530,232 - $748,025	-8,458 Reduced 27.67%	22,113 $1.66 Million
Q1 2022 May 13, 2022	SELL	$63.15 - $90.42 $399,423 - $571,906	-6,325 Reduced 17.14%	30,571 $2.39 Million
Q4 2021 Feb 14, 2022	SELL	$77.28 - $99.42 $147,063 - $189,196	-1,903 Reduced 4.9%	36,896 $3.32 Million
Q3 2021 Nov 12, 2021	BUY	$65.97 - $92.48 $290,333 - $407,004	4,401 Added 12.79%	38,799 $3.59 Million
Q2 2021 Aug 12, 2021	BUY	$69.38 - $86.75 $103,237 - $129,084	1,488 Added 4.52%	34,398 $2.67 Million
Q1 2021 May 13, 2021	SELL	$72.25 - $168.95 $1.2 Million - $2.81 Million	-16,654 Reduced 33.6%	32,910 $2.45 Million
Q4 2020 Feb 09, 2021	BUY	$125.56 - $178.74 $250,492 - $356,586	1,995 Added 4.19%	49,564 $8.45 Million
Q3 2020 Nov 06, 2020	BUY	$127.12 - $172.34 $349,071 - $473,245	2,746 Added 6.13%	47,569 $6.68 Million
Q2 2020 Aug 12, 2020	BUY	$93.0 - $171.7 $544,422 - $1.01 Million	5,854 Added 15.02%	44,823 $7.19 Million
Q1 2020 May 11, 2020	BUY	$82.38 - $131.64 $855,351 - $1.37 Million	10,383 Added 36.32%	38,969 $3.81 Million
Q4 2019 Feb 13, 2020	BUY	$76.53 - $135.58 $136,988 - $242,688	1,790 Added 6.68%	28,586 $3.69 Million
Q3 2019 Nov 12, 2019	BUY	$72.81 - $156.91 $103,608 - $223,282	1,423 Added 5.61%	26,796 $2.02 Million
Q2 2019 Aug 13, 2019	BUY	$112.21 - $151.95 $699,068 - $946,648	6,230 Added 32.54%	25,373 $3.86 Million
Q1 2019 May 14, 2019	SELL	$106.67 - $151.68 $463,694 - $659,352	-4,347 Reduced 18.51%	19,143 $2.28 Million
Q4 2018 Feb 14, 2019	SELL	$97.32 - $148.76 $592,192 - $905,204	-6,085 Reduced 20.57%	23,490 $2.56 Million
Q3 2018 Nov 13, 2018	SELL	$115.31 - $161.51 $51,312 - $71,871	-445 Reduced 1.48%	29,575 $4.78 Million
Q2 2018 Aug 13, 2018	SELL	$71.74 - $153.69 $255,035 - $546,367	-3,555 Reduced 10.59%	30,020 $3.97 Million
Q1 2018 May 15, 2018	SELL	$54.02 - $82.27 $617,718 - $940,757	-11,435 Reduced 25.41%	33,575 $2.49 Million
Q4 2017 Feb 14, 2018	BUY	$47.64 - $56.75 $36,921 - $43,981	775 Added 1.75%	45,010 $2.5 Million
Q3 2017 Nov 13, 2017	BUY	$35.73 - $47.15 $1.58 Million - $2.09 Million	44,235	44,235 $2.01 Million

Others Institutions Holding SRPT

# of Institutions

531

Shares Held

84.5M

Call Options Held

2.06M

Put Options Held

1.52M

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $9.71B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.

Account